相关实验视频
Updated: Sep 16, 2025
13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
27.9K
中性粒细胞与淋巴细胞的比例作为喘识别和严重程度分层的生物标志物:系统性审查和元分析
Lei Jin1, Jie Guo2, Keting Deng3
1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China.
Frontiers in medicine
|July 9, 2025
概括
中性粒细胞与淋巴细胞的比率 (NLR) 是一个有前途的生物标志物,用于识别喘及其严重程度. 虽然有效区分喘患者和健康个体,但其区分中度和重度喘的能力有限.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 生物标志物研究 生物标志物研究
背景情况:
- 喘诊断和严重程度评估缺乏可靠的生物标志物.
- 中性粒细胞与淋巴细胞的比率 (NLR) 是一种潜在的,但不一致的喘生物标志物.
- 这项研究调查了NLR在喘中的诊断和预后价值.
研究的目的:
- 评估NLR在将喘患者与健康对照患者区分开来方面的有效性.
- 评估NLR水平与喘严重程度之间的相关性.
- 确定NLR作为喘识别和分层的生物标志物的潜力.
主要方法:
- 在PubMed,Embase和Web of Science进行系统的文献搜索.
- 使用随机效应模型对聚合平均差异 (MD) 和95%置信区间 (CI) 的元分析.
- 接收器运行特征 (ROC) 曲线分析以评估区分性性能.
主要成果:
- 分析了19项涉及43,164名喘患者和8,411名对照者的研究.
- 在NLR中,喘与对照群 (AUC=0.929) 和严重与不严重的喘 (AUC=0.914) 之间有强有力的区别.
- 在喘严重程度之间观察到NLR的显著增量增加,特别是在严重和不严重的喘之间 (MD=-2.06,p<0.0001).
结论:
- NLR是喘诊断和严重程度分层的一个有价值的生物标志物.
- 在区分严重的喘和较轻的形式方面,NLR显示出潜在的潜力.
- 需要进一步的研究来探索NLR在预测喘进展和恶化中的作用.
相关概念视频
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:19Antiasthma Drugs: Leukotriene Modifiers
489
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
489